Early experience with novel immunomodulators for cancer treatment (Q28241744)

Expert Opinion on Investigational Drugs

Europe PubMed Central

title

Early experience with novel immunomodulators for cancer treatment (English)

0 references

author name string

Ziad Thotathil

series ordinal

1

0 references

Michael B Jameson

series ordinal

2

0 references

language of work or name

English

0 references

publication date

September 2007

0 references

published in

0 references

volume

16

0 references

issue

9

0 references

page(s)

1391-403

0 references

cites work

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Pathogen recognition and innate immunity

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Human lung cancer cells express functionally active Toll-like receptor 9

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Thalidomide is an inhibitor of angiogenesis

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Antiviral activities of lactoferrin

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Cancer prevention by natural compounds

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Targeting Tumor-Related Immunosuppression for Cancer Immunotherapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Cancer immunotherapy: moving beyond current vaccines

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

Adoptive immunotherapy for cancer: building on success

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.16.9.1391

The immunobiology of cancer immunosurveillance and immunoediting

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Biomodulators in cancer treatment

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

NIH conference. Immunomodulators in clinical medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

The treatment of melanoma with an emphasis on immunotherapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Chromosomal localization of TIL, a gene encoding a protein related to the Drosophila transmembrane receptor Toll, to human chromosome 4p14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

How we detect microbes and respond to them: the Toll-like receptors and their transducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

A conserved signaling pathway: the Drosophila toll-dorsal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Toll-like receptors on tumor cells facilitate evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Successful combination of local CpG-ODN and radiotherapy in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

CpG oligodeoxynucleotide enhances tumor response to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

The imidazoquinolines and their place in the therapy of cutaneous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Imiquimod in basal cell carcinoma: how does it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

IMiDs: a novel class of immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Thalidomide: a novel template for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Thalidomide in multiple myeloma: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase II study of thalidomide in patients with metastatic malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Antivascular therapy of cancer: DMXAA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Immunological ignorance of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

The therapeutic use of rituximab in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Combining radiotherapy and immunotherapy: a revived partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

On combining antineoplastic drugs with tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391

Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1391